Numbers of erythroblasts at different maturation stages in naive or P chabaudi AS–infected mice with or without EPO treatment
. | N . | N + EPO* . | I . | I + EPO* . |
---|---|---|---|---|
I: CD71highTER119low | 0.20 ± 0.07a | 6.93 ± 0.13b | 1.97 ± 0.58c | 5.79 ± 0.60d |
II: CD71highTER119high | 0.42 ± 0.17a | 11.27 ± 0.51b | 1.23 ± 0.33a,c | 2.05 ± 0.35c |
III: CD71low-medTER119high | 2.43 ± 0.59a | 57.60 ± 1.39b | 4.43 ± 1.14a | 10.93 ± 1.57c |
IV: CD71medTER119- | 1.51 ± 0.30a | 4.99 ± 0.09b | 19.61 ± 2.44c | 33.11 ± 2.22d |
. | N . | N + EPO* . | I . | I + EPO* . |
---|---|---|---|---|
I: CD71highTER119low | 0.20 ± 0.07a | 6.93 ± 0.13b | 1.97 ± 0.58c | 5.79 ± 0.60d |
II: CD71highTER119high | 0.42 ± 0.17a | 11.27 ± 0.51b | 1.23 ± 0.33a,c | 2.05 ± 0.35c |
III: CD71low-medTER119high | 2.43 ± 0.59a | 57.60 ± 1.39b | 4.43 ± 1.14a | 10.93 ± 1.57c |
IV: CD71medTER119- | 1.51 ± 0.30a | 4.99 ± 0.09b | 19.61 ± 2.44c | 33.11 ± 2.22d |
Erythroblasts were identified by double staining with FITC-conjugated anti-CD71 and PE-conjugated anti-TER119 antibodies. Region I: proerythroblasts. Region II: basophilic erythroblasts. Region III: polychromatic and orthochromatic erythroblasts. Region IV: nonerythroblast population expressing CD71. Data are means ± SEM × 106 cells per spleen for 3 to 5 mice per group. When 2 sets of data are labeled with superscripts of lowercase letters, it indicates that these 2 sets of data are statisitcally different (P < .05). Similar results were obtained in 2 independent experiments.
Abbreviations are explained in the footnotes to Table 1.
Naive or infected A/J mice were treated with 10 units of rmEPO per day for 3 consecutive days. Mice were humanely killed 1 day following the completion of the treatment, and spleen parameters were assessed.